|
Volumn 20, Issue 3, 2014, Pages 394-395
|
Removing the bone brake
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALENDRONIC ACID;
BIOLOGICAL MARKER;
BISPHOSPHONIC ACID DERIVATIVE;
NEUTRALIZING ANTIBODY;
OSTEOPROTEGERIN;
PARATHYROID HORMONE;
PARATHYROID HORMONE[1-34];
RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;
ROMOSUZUMAB;
SCLEROSTIN;
UNCLASSIFIED DRUG;
DENOSUMAB;
ROMOSOZUMAB;
BONE DENSITY CONSERVATION AGENT;
MONOCLONAL ANTIBODY;
ADULT;
AGED;
ARTICLE;
BONE;
BONE DENSITY;
BONE MASS;
BONE MINERAL;
CELL DIFFERENTIATION;
FEMALE;
HUMAN;
LUMBAR SPINE;
MAJOR CLINICAL STUDY;
MAMMAL;
OSSIFICATION;
OSTEOBLAST;
OSTEOCYTE;
OSTEOLYSIS;
OSTEOPOROSIS;
PHASE 2 CLINICAL TRIAL (TOPIC);
POSTMENOPAUSE;
POSTMENOPAUSE OSTEOPOROSIS;
PRIORITY JOURNAL;
ANKYLOSIS;
BONE METABOLISM;
BONE REMODELING;
DRUG EFFECTS;
OSTEOPOROSIS, POSTMENOPAUSAL;
ANTIBODIES, MONOCLONAL;
BONE DENSITY;
BONE DENSITY CONSERVATION AGENTS;
BONE REMODELING;
FEMALE;
HUMANS;
OSTEOPOROSIS, POSTMENOPAUSAL;
|
EID: 84913585356
PISSN: 15504131
EISSN: 19327420
Source Type: Journal
DOI: 10.1016/j.cmet.2014.08.009 Document Type: Short Survey |
Times cited : (4)
|
References (10)
|